Literature DB >> 35190960

Anti-inflammatory and Immunomodulatory Potency of Selenium-Enriched Probiotic Mutants in Mice with Induced Ulcerative Colitis.

Abd El-Nasser Khattab1, Ahmed M Darwish2, Sarah I Othman3, Ahmed A Allam4, Haifa A Alqhtani3.   

Abstract

Selenium-enriched Lactobacillus plantarum and Bifidobacterium longum mutants were used as a protector against Piroxicam-induced ulcerative colitis (UC). In this study, 32 BALB/c male mice were distributed to four groups: the control group, the Piroxicam group which was given 0.8 mg Piroxicam, SP and SB groups which were given 0.8 mg Piroxicam, and plus Lactobacillus plantarum and Bifidobacterium longum selenium-enriched mutants, respectively. Bodyweight; serum content of IgG, IgM, TNF-α, IL-2, IL-6, and IL-10; CBC; myeloperoxidase enzyme activity; histopathological examination of colon and spleen; and expression of TNF-α, IL-2, IL-6, and IL-10 genes in colon and spleen with qRT-PCR were determined. Bodyweight was found to reduce in the Piroxicam group and then recovery in the SB group. Serum content of IgG, IL-2, and IL-10 reduced in the Piroxicam group, whereas IgG, TNF-α, and IL-6 increased in the Piroxicam group in comparison to the other groups. Myeloperoxidase activity witnessed a significant increase in the Piroxicam group compared with the other groups. No significant differences were observed between all groups in measurements of red cells, hemoglobin, neutrophil, monocyte, eosinophil, and basophil in blood. Meanwhile, the white blood cells and platelets recorded the highest and lowest value, respectively, in the Piroxicam group. The colon of the Piroxicam group showed a noticeably massive infiltration of inflammatory cells in the lamina propria. These inflammations were mildly reduced in the SP group, while the reduction in the SB group was significant. In the Piroxicam group, splenic parenchyma saw an increase in the number of melanomacrophages, while hypertrophic plasma cells were observed in the SP group. The spleen of the SB group exhibits a nearly normal form. TNF-α and IL-6 genes had significantly upregulated in the colon of the Piroxicam group compared to the control group, while they were significantly downregulated in the SB group. In contrast, IL-2 and IL-10 genes had upregulated in the colon of the SB group compared to the control groups, while they had downregulated in the Piroxicam group. The expression of these genes had not recorded significant differences between all groups in the spleen. Therefore, this study recommends Bifidobacterium longum selenium-enriched mutants as anti-inflammatory and immunomodulatory supplements.
© 2022. The Author(s).

Entities:  

Keywords:  Anti-inflammatory; Mice; Probiotic mutant; Selenium; Ulcerative colitis

Year:  2022        PMID: 35190960     DOI: 10.1007/s12011-022-03154-1

Source DB:  PubMed          Journal:  Biol Trace Elem Res        ISSN: 0163-4984            Impact factor:   3.738


  16 in total

Review 1.  Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update.

Authors:  John M Kyriakis; Joseph Avruch
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.

Authors:  M-I Torres; A Rios
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

3.  Synbiotic combination of prebiotic grape pomace extract and probiotic Lactobacillus sp. reduced important intestinal inflammatory markers and in-depth signalling mediators in lipopolysaccharide-treated Caco-2 cells.

Authors:  Gina Cecilia Pistol; Daniela Eliza Marin; Catalin Dragomir; Ionelia Taranu
Journal:  Br J Nutr       Date:  2018-12-19       Impact factor: 3.718

4.  Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation.

Authors:  I B Autenrieth; N Bucheler; E Bohn; G Heinze; I Horak
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

5.  Antagonistic action of Lactobacillus lactis toward Salmonella spp. and Escherichia coli O157:H7 during growth and refrigerated storage.

Authors:  M M Brashears; W A Durre
Journal:  J Food Prot       Date:  1999-11       Impact factor: 2.077

Review 6.  The gnotobiotic animal as a tool in the study of host microbial relationships.

Authors:  H A Gordon; L Pesti
Journal:  Bacteriol Rev       Date:  1971-12

Review 7.  Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.

Authors:  Benjamin Misselwitz; Pascal Juillerat; Michael Christian Sulz; Britta Siegmund; Stephan Brand
Journal:  Digestion       Date:  2020-06-22       Impact factor: 3.216

Review 8.  Strategies for the development of selenium-based anticancer drugs.

Authors:  Philippe Collery
Journal:  J Trace Elem Med Biol       Date:  2018-03-08       Impact factor: 3.849

9.  The Immunostimulatory Effect of Lactic Acid Bacteria in a Rat Model.

Authors:  Murat Karamese; Hakan Aydin; Emin Sengul; Volkan Gelen; Cigdem Sevim; Duran Ustek; Emre Karakus
Journal:  Iran J Immunol       Date:  2016-09       Impact factor: 1.603

10.  Interesting probiotic traits of mother's milk Lactobacillus isolates; from bacteriocin to inflammatory bowel disease improvement.

Authors:  Milad Abdi; Vahid Lohrasbi; Arezoo Asadi; Maryam Esghaei; Faramarz Masjedian Jazi; Mahdi Rohani; Malihe Talebi
Journal:  Microb Pathog       Date:  2021-05-24       Impact factor: 3.738

View more
  2 in total

1.  Selenium-enriched Bifidobacterium longum DD98 effectively ameliorates dextran sulfate sodium-induced ulcerative colitis in mice.

Authors:  Yongjia Hu; Xueli Jin; Fei Gao; Ting Lin; Hui Zhu; Xiao Hou; Yu Yin; Shidong Kan; Daijie Chen
Journal:  Front Microbiol       Date:  2022-08-05       Impact factor: 6.064

2.  Effectiveness of new selenium-enriched mutated probiotics in reducing inflammatory effects of piroxicam medication in liver and kidney.

Authors:  Ahmed Mohamed Darwish; Abd El-Nasser A Khattab; Khaled A Abd El-Razik; Sarah I Othman; Ahmed A Allam; Gasem M Abu-Taweel
Journal:  Inflammopharmacology       Date:  2022-09-09       Impact factor: 5.093

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.